Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 4 1Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Tumor Lysis Syndrome 3Recurrence 1Neoplasms 1Lymphoma 1Leukemia 1Hyperuricemia 1Hematologic Neoplasms 1

Interventions

pegylated granulocyte colony-stimulating factor 4entecavir 3Granulocyte Colony-Stimulating Factor 3Cyclophosphamide 3Brentuximab Vedotin 3Aprepitant 3Vinblastine 2Prednisolone 2Doxorubicin 2Dexamethasone 2rasburicase 1prednylidene 1plerixafor 1peginterferon alfa-2b 1pegfilgrastim 1golimumab 1fludarabine phosphate 1fludarabine 1fluarix 1ferrous succinate 1dexamethasone 21-phosphate 1arexvy 1abrysvo 1Zidovudine 1Water 1Watchful Waiting 1Vindesine 1Vincristine 1Valproic Acid 1Urate Oxidase 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Lymphoma × Urate Oxidase × Clear all
NCT00230217 2009-03-30

Study of Rasburicase as Treatment or Prevention of Hyperuricemia Associated With Tumor Lysis Syndrome in Patients With Relapsed or Refractory Lymphoma, Leukemia, or Solid Tumor Malignancy

Sanofi

Phase 4 Completed
94 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Neoplasms, Recurrence, Tumor Lysis Syndrome, Hyperuricemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡